Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Heart Damage Equipment Supplied In Europe
5 equipment items found
Manufactured by:advanceCOR GmbH based inPlanegg, GERMANY
This is the name of our therapeutic agent for the prevention of stroke and heart attack. Its principle effectiveness has already been proven in patients. It is a soluble protein which, when blood vessels are damaged, covers the damaged areas. Revacept is designed to protect the vessel walls so that vascular occlusion does not occur. ...
Manufactured by:Vitrosens Biotechnology A.S. based inÜmraniye, TURKEY
Test kit is specifically designed for the qualitative determination of Creatine kinase-MB (CK-MB) protein in human serum, plasma, and whole blood ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
NHIE is acute or sub-acute brain injury due to asphyxia caused during birth resulting from deprivation of oxygen during birth (hypoxia) as a result of a sentinel event such as ruptured placenta, parental shock and even increased heart rate. Hypoxic damage can occur to most of the infant’s organs, but brain damage is the most serious and ...
Manufactured by:CellProthera based inMulhouse, FRANCE
The unique therapeutic approach proposed by CellProthera is protected by various patents. It requires a simple blood sampling best performed within 2 weeks following a severe AMI. The sampling occurs after a treatment period using GCSF in order to mobilize the patient’s own stem cells into the blood flow. The patient’s blood sample is then forwarded to a local certified Cell Therapy ...
Manufactured by:Therawis based inMunich, GERMANY
The acute SARS-CoV-2 infection is diagnosed routinely through PCR-based detection of viral RNA from nasopharyngeal swabs. Additionally, direct antigen detection of viral proteins is now available. The specific detection by PCR has a high sensitivity and specificity but delivers a false-negative rate of up to 38 % at the time of symptoms (Kucirka et al. 2020). The sensitivity and specificity of ...